Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab + TAS-102 for Advanced Gastric/GEJ Cancer
NCT04660760Phase 2Recruiting
- Sponsor
- Academic and Community Cancer Research United
- Start
- Jun 2021
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trifluridine + tipiracil in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Academic and Community Cancer Research United. Started Jun 2021; status: recruiting.
02
Drugs
trifluridine + tipiracil
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04660760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04660760.